{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:26:40Z","timestamp":1787038000824,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00228-026-04078-8","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:40:41Z","timestamp":1784619641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mass balance study of [14C]-ABBV-552, a synaptic vesicle glycoprotein 2A positive modulator, in healthy male participants following single oral dose administration"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-9694","authenticated-orcid":false,"given":"Nick","family":"Miles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9513-9359","authenticated-orcid":false,"given":"Brian","family":"McNamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4557-6402","authenticated-orcid":false,"given":"Sharif I.","family":"Soleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-1704","authenticated-orcid":false,"given":"Cindy","family":"Zadikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5623-2489","authenticated-orcid":false,"given":"Joey","family":"Boiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6082-9430","authenticated-orcid":false,"given":"Loic","family":"Laplanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2880-2207","authenticated-orcid":false,"given":"Richard","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-8933","authenticated-orcid":false,"given":"Mohamad","family":"Shebley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-9210","authenticated-orcid":false,"given":"Ramesh R.","family":"Boinpally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"4078_CR1","doi-asserted-by":"publisher","first-page":"864514","DOI":"10.3389\/fnins.2022.864514","volume":"16","author":"R Rossi","year":"2022","unstructured":"Rossi R, Arjmand S, B\u00e6rentzen SL, Gjedde A, Landau AM (2022) Synaptic vesicle glycoprotein 2A: features and functions. Front Neurosci 16:864514","journal-title":"Front Neurosci"},{"key":"4078_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41386-024-01943-x","volume":"50","author":"O Howes","year":"2025","unstructured":"Howes O, Marcinkowska J, Turkheimer FE, Carr R (2025) Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging. Neuropsychopharmacology 50:164\u2013183","journal-title":"Neuropsychopharmacology"},{"key":"4078_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","volume":"30","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H (2016) Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs 30:1055\u20131077","journal-title":"CNS Drugs"},{"key":"4078_CR4","doi-asserted-by":"publisher","first-page":"1066447","DOI":"10.3389\/fphar.2022.1066447","volume":"13","author":"W Botermans","year":"2023","unstructured":"Botermans W, Koole M, Laere KV, Savidge JR, Kemp JA, Sunaert S, Duffy MM, Ramael S, Cesura AM, D\u2019Ostillo K, Gossen D, Madsen TM, Lodeweyckx T, de Hoon J (2023) SDI-118, a novel procognitive SV2A modulator: first-in-human randomized controlled trial including PET\/fMRI assessment of target engagement. Front Pharmacol 13:1066447","journal-title":"Front Pharmacol"},{"key":"4078_CR5","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/alz.063947","volume":"18","author":"SY Lynch","year":"2022","unstructured":"Lynch SY, Jia J, Miles N, Boiser J, Buhl DL, Graff O, Zadikoff C (2022) ABBV-552 in patients with mild Alzheimer\u2019s disease: a randomized phase IIb trial. Alzheimers Dement 18:1957\u20131968","journal-title":"Alzheimers Dement"},{"key":"4078_CR6","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1111\/cts.13403","volume":"15","author":"A Ramamoorthy","year":"2022","unstructured":"Ramamoorthy A, Bende G, Chow ECY, Dimova H, Hartman N, Jean D, Pahwa S, Ren Y, Shukla C, Yang Y, Doddapaneni S, Danielsen ZY (2022) Human radiolabeled mass balance studies supporting the FDA approval of new drugs. Clin Transl Sci 15:2567\u20132575","journal-title":"Clin Transl Sci"},{"key":"4078_CR7","first-page":"792","volume":"8","author":"P Coppola","year":"2019","unstructured":"Coppola P, Andersson A, Cole S (2019) The importance of the human mass balance study in regulatory submissions. CPT: Pharmacomet Syst Pharmacol 8:792\u2013804","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"key":"4078_CR8","unstructured":"US Food and Drug Administration (2024) Clinical pharmacology considerations for human radiolabeled mass balance studies: guidance for industry. Accessed 14 Aug 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-human-radiolabeled-mass-balance-studies"},{"key":"4078_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/clpt.1981.56","volume":"29","author":"RA Hamilton","year":"1981","unstructured":"Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408\u2013413","journal-title":"Clin Pharmacol Ther"},{"key":"4078_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/js970486q","volume":"87","author":"CECA Hop","year":"1998","unstructured":"Hop CECA, Wang Z, Chen Q, Kwei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901\u2013903","journal-title":"J Pharm Sci"},{"key":"4078_CR11","unstructured":"US Food and Drug Administration (2020) Safety testing of drug metabolites: guidance for industry. Accessed 26 Sept 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-testing-drug-metabolites"},{"key":"4078_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2165\/00003088-199223040-00005","volume":"23","author":"HK Kroemer","year":"1992","unstructured":"Kroemer HK, Klotz U (1992) Glucuronidation of drugs. Clin Pharmacokinet 23:292\u2013310","journal-title":"Clin Pharmacokinet"},{"key":"4078_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/03602530600952172","volume":"39","author":"SJ Roffey","year":"2007","unstructured":"Roffey SJ, Obach RS, Gedge JI, Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17\u201343","journal-title":"Drug Metab Rev"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04078-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:27Z","timestamp":1787036127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04078-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4078"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04078-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NM, BM, SIS, CZ, JB, RB, MS, and RRB are employees of AbbVie Inc. and may hold stock and\/or stock options in the company. LL is a former employee of AbbVie, a current employee of BIODOL Therapeutics, and may hold stock and\/or stock options in the companies.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"214"}}